Markets:

Overview

News

Currencies

International

Treasuries

Trevi Therapeutics, Inc. - Common Stock (NQ:TRVI)

10.44 -0.07 (-0.67%)

Streaming Delayed Price Updated: 11:38 AM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Trevi Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

MarketBeat’s Top 5 Rated Small-Cap Stocks ↗

December 22, 2025

Via MarketBeat

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Via The Motley Fool

Topics Regulatory Compliance

Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Plans ↗

November 13, 2025

Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.

Via Chartmill

Earnings Preview For Trevi Therapeutics ↗

May 07, 2025

Via Benzinga

A Peek at Trevi Therapeutics's Future Earnings ↗

November 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 03, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

August 21, 2025

Via Benzinga

Dow Gains Over 100 Points; US Job Openings Increase In April ↗

June 03, 2025

Via Benzinga

Topics Stocks

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients ↗

June 02, 2025

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant results at multiple doses.

Via Benzinga

Earnings Scheduled For March 18, 2025 ↗

March 18, 2025

Via Benzinga

Unusual volume stocks are being observed in Tuesday's session. ↗

March 11, 2025

In today's session, these stocks are experiencing unusual volume.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 10, 2025

The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday ↗

March 10, 2025

Via Benzinga

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps ↗

March 10, 2025

Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.

Via Benzinga

Top movers in Monday's pre-market session ↗

March 10, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket ↗

March 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 12, 2024

Via Benzinga

Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher ↗

December 12, 2024

Via Benzinga

Topics Stocks

Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook ↗

December 12, 2024

Via Benzinga

Nasdaq Down 50 Points; US Initial Jobless Claims Rise ↗

December 12, 2024

Via Benzinga

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? ↗

December 12, 2024

Trevi Therapeutics' CORAL trial progresses unchanged after a positive SSRE review, with topline results for chronic cough in IPF expected by mid-2025.

Via Benzinga

TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024 ↗

August 08, 2024

TRVI stock results show that Trevi Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.